Innovation projects are thematically addressing the greatest societal health challenges that EIT Health intends to address with its strong network. The aim is to achieve rapid market penetration of innovative projects and services and to test and implement novel organizational provision processes in European healthcare.
The most promising ideas are developed through a multidisciplinary approach involving commercial, medical, IT and other knowledge areas into commercially viable products.
More Information on iPDM-GO can be found on this website.
Diabetes mellitus represents a major and multi-dimensional challenge for humanity. In 2017, the International Diabetes Federation (IDF) estimated that there are approximately 425 million people with diabetes worldwide, and their numbers continue to rise. Therefore, providing cost-effective healthcare services tailored to the individual needs and needs of each patient is crucial.
Integrated Personalized Diabetes Management Goes Europe (iPDM-GO) is committed to solving this problem. It is a therapeutic approach that structures the treatment process, connects HCPs and patients, and integrates digital data visualization and analysis tools.
Inflammatory respiratory diseases are often diagnosed too late. Every year, respiratory diseases in the EU are responsible for 600 000 deaths and 6 million hospital visits, as well as social costs of 200 billion euros. ADAPT combines two innovations to develop a novel diagnostic kit that allows earlier and more accurate assessment of inflammatory airways disease, allowing better intervention and personalized treatment.
More than 28 million people in Europe are visually impaired due to retinal diseases. The current diagnosis is based on the identification of a large-scale change in the retina, which is usually recognized by conventional ophthalmological instruments only when the patient has already suffered irreversible vision loss. ASSESS is developing a revolutionary system that enables rapid, non-invasive imaging of patients’ retinal cells. Early diagnosis of retinal diseases, one of the main causes of blindness, can improve the treatment and increase the chances of prevention.
External Project Partner:
Trier University Of Applied Sciences
CLAIRE develops an “Alexa with a PhD”, an innovative virtual healthcare assistant to address one of the main challenges in today’s intensive care units: Medical knowledge and data increases each day – doctors and nurses spend 50% of their day in front of computer screens instead of interacting with the patients. CLAIRE‘s virtual medical assistant combines state-of-the-art advances of Machine Learning, Natural Language Processing and Artificial Intelligence with an intuitive human interface to support doctors and nurses at the Intensive Care Unit with documentation, disease detection and accurate, evidence-based treatment.
More information on CLOSE can be found on this website.
The artificial pancreas (AP) is approaching a “technical cure” for diabetes by measuring the level of glucose and using an algorithm to determine the right amount of insulin for the patient. CLOSE strives to improve the care and quality of life of Type 2 diabetes patients by improving the AP with appropriate product and service packages to create AP +. By adding training (train-the-trainer), telemedicine counseling, and performance forecasting and performance measurement tools to the APs, CLOSE will increase AP effectiveness and reimbursement.
This project aims to improve the inefficient Influenza care pathway and overcome additional post approval obstacles hindering widespread adoption of a new solution. An unique (cobas® Liat®) laboratory-based testing methodology into an easy-to-use and compact solution to allow medical care at the “bedside” for patients at risk of influenza (“flu”). The addition of the Liat® to the clinical pathway will reduce hospital admissions and potentially the rate of transmission of the disease, unnecessary antibiotic prescribing for viral infection and flu-associated morbidity and mortality from secondary bacterial infections. The project will generate the clinical and economic evidence necessary to support decision-making and expanded rollout of the technology, in order to rapidly accelerate access to the latest diagnostic technology and improve flu-related outcomes for patients.
Mehr Information zu FRAIL finden Sie auf dieser Webseite
The identification and assessment of frailty in the treatment of the elderly is essential to tailoring geriatric interventions to the needs of individuals. The currently available instruments for assessing individual frailty, which require time-consuming screening processes, are difficult to apply in primary care. FRAIL is a smartwatch app development project that supports older people who are in a frail state. The app monitors falls, physical activity and disruption of routine activities to detect the onset of frailty and avoid its consequences on the wearer.
Chronic obstructive pulmonary disease (COPD) is a progressive, life-threatening lung disease characterized by respiratory distress and coughing. There are 250 million COPD patients worldwide, and it is the fourth most common cause of death, responsible for 3 million deaths per year. HomeCare@COPD will enhance intensive care at home for people with lung disease by providing patients with insight into RAS-Q, the so-called “Lung In A Backpack” – the world’s first portable ventilation device for long-term COPD treatment, that was developed with support of EIT Health.
Each year, more than 1 million EU citizens suffer from a stroke, and up to 30% suffer from homonymous hemianopia (HH), a complex visuomotor deficit caused by a stroke in the visual cortex and associated with the loss of a visual half-field. MARNIE helps treat visuomotor deficiencies that cause problems with eye-hand coordination in patients after a stroke. A new therapy is used that combines augmented reality goggles with low-power stimulation of the skull to train the brain.
Over the last decade, groundbreaking research into understanding the immune system and unlocking its anti-tumor potential has led to adoptive cell therapies with the potential to eliminate tumors that resist conventional and targeted therapies. It has been demonstrated that T cell responses to mutated peptide ligands that serve as neoantigens on cancer cells mediate anti-tumor responses. NEOSPECT will revolutionize cancer treatment by combining two novel clinical concepts: adoptive cell therapy and the targeted treatment of tumor-specific neoantigens. This combination will allow patient-specific T cell products to be clinically produced in a cost-effective, safe and automated process.
More than 50 million people worldwide suffer from epilepsy, making it one of the most common neurological diseases worldwide. Inaccurate seizure messages pose a major challenge to diagnosing and treating people with epilepsy. SeizeIT2 is a clinically accurate seizure detection system for people with epilepsy. This discrete portable device monitors multiple biosignals to provide a more accurate quantitative analysis of seizure activity so that people with epilepsy can receive optimized treatment for their specific condition.
Affairs around the effectiveness, costs & market availability of drugs challenge the public confidence in pharma industry and treatments and impact healthcare sustainability. A key underlying cause is the limited usage of real-world information in both drug development and disease management. The shortage of real-world data limits the predictive power of clinical trials and thereby the quality of early decision making in drug development – leading to high attrition rates and even withdrawals of drugs from the market. RealWorld4Clinic will accelerate market launch of a coin-sized medical device anchored to the fundus of the stomach. There it acquires real-life cardio-respiratory health data for exploitation in drug development and tele-cardiology. The clinical trial market will be the stepping stone towards outpatient cardiological care – our priority market. The device will be enriched by remote monitoring & data exploitation, training & education, and outcome prediction & performance measurement tools.
Drug-induced cardiac and neuronal toxicities represent major complications in the daily clinical routine and are the major cause for attrition during early drug development and post market withdrawal. Since conventional drug screenings rely on in vivo and in vitro animal models with limited translational capacity, there is an urgent need for translational assays, which are able to predict drug-induced toxicities in humans in a robust and reliable manner. The R2U-Tox-Assay project aims to push the limits of medical care with an innovative approach that will strengthen the healthcare system as a whole. The reliable detection of drug-induced toxicities with high-quality, ready-to-use toxicity assays at a moderate price will have an immediate impact on the patient’s health by averting potentially fatal and costly side effects.
Do you have any questions about the current EIT Health Business Plan, the application, training or deadlines? Here you will find answers to the most important questions about your partnership with EIT Health Germany.
Innovation Projects aim at (1) the rapid market penetration of innovative products and services, and/or (2) the testing and implementation of novel organisational and healthcare delivery processes.
The maximum EIT available funding is €1 million per year per project for a maximum duration of 36 months.
EIT Health Innovation Projects support innovative approaches in biotech, medtech and digital health that have left the phase of ground research and heading towards market approval and first customers.
As a support, we recommend making use of the CIMIT Innovation Maturity Level (IML) that measures the maturity of an innovation on four dimensions:
Ideally, you should have reached a “proof of concept”-level for all four dimensions. Find further information here: https://cimit.org/documents/173804/228699/Navigating+the+HealthTech+Innovation+Cycle.pdf/2257c90b-d90b-3b78-6dc9-745db401fbc6?version=1.0
All innovation project proposals must involve Core or Associate Partners from a minimum of two CLC/InnoStars. The consortium must include at least one academic and one non-academic Core or Associate Partner, i.e. one Partner of the type “Education” or “Research” and one of any other type.
You will find a list here: www.eithealth.eu/partners
You can include External Project Partners that are not EIT Health Core or Associate Partners, e.g. start-ups and SMEs. The maximum funding for External Project Partners is 50.000 EUR / year.
For an EIT Health Innovation Project, you will be able to incur (pre)existing costs of the development of your innovation. These costs are called “KIC complementary activities (KCA)”. The funding ratio for 25% EIT funding (= “KIC Added-Value Activity (KAVA)”) versus 75% funding of other resources (e.g. other public grants, inhouse resources etc.). In general, EIT accepts costs from 2015 and/or in parallel to the duration of the project.
Example: If you ask for 3M € EIT-funding for your Innovation Project, you will have to demonstrate 9M € costs covered by other resources.
All proposals need to be submitted on the EIT Health online platform PLAZA: www.plaza.eithealth.eu
Please make sure that all your consortium partners have individual PLAZA-accounts. You will need to add them to the work packages and budget lines in the proposal. Otherwise they will not be able to receive EIT funding.
If you are a newbie to PLAZA, please reserve at least two full days. One day would help to familiarize yourself with the logic of connecting work packages, costs and KPIs/outputs/deliverables. The second day will be needed to enter the details into the system.
The German CLC supports Innovation Projects from an early project ideation phase until the final submission and evaluation phase.
The support includes for example:
Do you have any further questions? I will be happy to inform you about your opportunities to participate in an EIT Health innovation project and assist you in brainstorming, networking with relevant EIT Health partners, submitting an application and in all further steps of your innovation project within the framework of the EIT Health Business Plan.